Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States

• DOI: 10.1007/s41669-018-0100-5
• Publication Date: 2018-10-15T05:40:02Z
• Authors: Jill A. Bell; Aaron Galaznik; Marlo Blazer; Huai-Che Shih; Eileen Farrelly; Augustina Ogbonnaya; Michael Eaddy; Robert J. Fram; Douglas V. Faller
• Keywords: Interquartile range

Significant clinical burden is associated with higher-risk myelodysplastic syndromes (HR-MDS); however, the economic has not been fully examined. We examined cost of care and healthcare utilization (HCU) in HR-MDS patients engaged routine United States (US).Adult US diagnosed from 1/1/2008 to 10/31/2015 were identified Optum database. Patients followed until death, progression acute myeloid leukemia (AML), end enrollment, or study (12/31/2015). Myelodysplastic syndrome (MDS)-related costs/HCU (including medical/pharmacy claims a primary diagnosis MDS, MDS-related treatment, supportive care) non-MDS-related evaluated. Costs calculated as per-patient per-month (PPPM) costs adjusted 2015 dollars.Of 209 included, median follow-up was 9.9 months (interquartile range 4.6-17.9), 69.4% had at least one inpatient admission, 56.9% emergency department visit, nearly all outpatient visit. Average PPPM over $17,361; year 1 versus 2 higher ($17,337 vs $12,976) following diagnosis. The majority for medical services ($10,327 PPPM). decreased $10,557 (year 1) $6530 2). main drivers decrease chemotherapy costs.The considerable, particularly within first Treatment/supportive accounted significant portion costs. As treatment evolves, impact HCU need be further investigated.